Organogenesis (ORGO) Registration Filing summary

Company overview and business model

• Focuses on regenerative medicine, developing and commercializing solutions for Advanced Wound Care and Surgical & Sports Medicine markets.

• Offers a comprehensive portfolio of products, including FDA-approved and 510(k) cleared therapies for chronic and acute wounds.

• Serves hospitals, wound care centers, government facilities, ambulatory surgery centers, and physician offices.

• Leverages clinical trials, real-world outcomes, and health economics research to validate product efficacy and value.

• Maintains a robust product pipeline supported by multiple technology platforms.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, commercialization, manufacturing, R&D, regulatory affairs, clinical trials, acquisitions, investments, and debt or stock repurchases.

• Will not receive proceeds from the sale of Class A common stock by selling securityholders.

Risk factors and disclosures

• Investment involves significant risks, including those detailed in the most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

• Additional risks may arise that could materially impact business operations and investment value.